Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
HIMS CEO Says 'A Little Bit of Craziness' Is The Secret To Building A Global Health Platform
10:34am, Tuesday, 04'th Nov 2025
Hims & Hers Health Inc (NYSE:HIMS) isn't just chasing wellness trends — it's building a global health platform. At the company's third-quarter earnings call, CEO Andrew Dudum said the company's next
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?
12:01am, Tuesday, 04'th Nov 2025
Investors looking for stocks in the Medical Info Systems sector might want to consider either Omnicell (OMCL) or Hims & Hers Health, Inc. (HIMS). But which of these two stocks offers value investors a
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates
11:58pm, Monday, 03'rd Nov 2025
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.06 per share a year ago.
Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript
10:26pm, Monday, 03'rd Nov 2025
Hims & Hers Health, Inc. ( HIMS ) Q3 2025 Earnings Call November 3, 2025 5:00 PM EST Company Participants Bill Newby Andrew Dudum - Co-Founder, Chairman & CEO Yemi Okupe - Chief Financial Officer Conf
Hims Says It's Negotiating A New Deal With Novo Nordisk; Shares Surge
05:43pm, Monday, 03'rd Nov 2025
Hims & Hers Health said late Monday it's in discussions with Novo Nordisk to sell Wegovy shots. The news buoyed Hims stock.
Hims & Hers Health Third-Quarter Revenue Jumps as Subscribers Grow
05:38pm, Monday, 03'rd Nov 2025
The telehealth platform said revenue rose 49% to $599 million in the latest quarter.
Hims & Hers Stock Pops After Q3 Earnings: Here's Why
04:35pm, Monday, 03'rd Nov 2025
Hims & Hers Health, Inc. (NYSE:HIMS) shares popped after the company released its third-quarter earnings report after Monday's closing bell. Hims said it is in active discussions to make Novo Nordisk
Hims and Hers misses quarterly profit estimates
04:12pm, Monday, 03'rd Nov 2025
Hims and Hers Health missed Wall Street estimates for third-quarter profit on Monday, hit by increased product costs and reduced unit sales in the telehealth company's weight-loss business.
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results
04:05pm, Monday, 03'rd Nov 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third
Hims & Hers Health (HIMS) to Release Quarterly Earnings on Monday
02:00am, Saturday, 01'st Nov 2025
Hims and Hers Health (NYSE: HIMS - Get Free Report) is projected to announce its Q3 2025 results after the market closes on Monday, November 3rd. Analysts expect Hims and Hers Health to post earnings
Hims & Hers Scales AI-Driven Personalized Health and Wellness
03:21pm, Friday, 31'st Oct 2025
HIMS scales AI-driven care with new hormonal health lines, global expansion plans and a $870 million funding boost.
Struggling Healthcare Stock Ripe For Bull Notes
02:30pm, Thursday, 30'th Oct 2025
Shares of Hims & Hers Health (HIMS) are headed for their fourth-straight daily drop, down 2.4% to trade at $45.53 at last check, as investors look ahead to the company's third quarter results, due out
Ethic Inc. Buys Shares of 7,048 Hims & Hers Health, Inc. $HIMS
04:04am, Thursday, 30'th Oct 2025
Ethic Inc. bought a new stake in Hims and Hers Health, Inc. (NYSE: HIMS) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought
Defiance Daily Target 2X Long HIMS ETF (NASDAQ:HIMZ) Short Interest Update
02:30am, Thursday, 30'th Oct 2025
Defiance Daily Target 2X Long HIMS ETF (NASDAQ: HIMZ - Get Free Report) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short int
LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.
02:48pm, Wednesday, 29'th Oct 2025
NEW YORK , Oct. 29, 2025 /PRNewswire/ -- A securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) is pending. The lawsuit was filed by Glancy Prongay & Murray LLP.
